111 related articles for article (PubMed ID: 36342355)
21. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
Kobayashi T; Makino T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Morii E; Eguchi H; Doki Y
Br J Cancer; 2021 Nov; 125(11):1523-1532. PubMed ID: 34599296
[TBL] [Abstract][Full Text] [Related]
22. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
24. Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC).
Yang J; Liu B; Li W; Xiong H; Qiu H; Fu Q; Chen B; Hu G; Yuan X
Cancer Epidemiol; 2013 Oct; 37(5):629-33. PubMed ID: 23837945
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.
Carrillo AM; Hicks M; Khabele D; Eischen CM
Mol Cancer Res; 2015 Aug; 13(8):1197-205. PubMed ID: 25964101
[TBL] [Abstract][Full Text] [Related]
27. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
[TBL] [Abstract][Full Text] [Related]
28. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
Gu L; Zhu N; Findley HW; Zhou M
Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
31. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma.
Taghavi N; Biramijamal F; Sotoudeh M; Khademi H; Malekzadeh R; Moaven O; Memar B; A'rabi A; Abbaszadegan MR
BMC Cancer; 2010 Apr; 10():138. PubMed ID: 20388212
[TBL] [Abstract][Full Text] [Related]
32. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
33. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.
Voon YL; Ahmad M; Wong PF; Husaini R; Ng WT; Leong CO; Lane DP; Khoo AS
Oncol Rep; 2015 Oct; 34(4):1692-700. PubMed ID: 26252575
[TBL] [Abstract][Full Text] [Related]
34. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
35. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
37. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
39. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
40. Chlorogenic acid inhibits esophageal squamous cell carcinoma growth in vitro and in vivo by downregulating the expression of BMI1 and SOX2.
Zhan Y; Li R; Feng C; Li X; Huang S; Wang L; Liu Z; Jiang J; Han Y
Biomed Pharmacother; 2020 Jan; 121():109602. PubMed ID: 31707349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]